- Clinical Pipeline
- Guadecitabine (SGI-110) DNMT inhibitor (Hematological Malignancies and Solid Tumors)
- ASTX029 Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
- Oral Decitabine and Cedazuridine (ASTX727) (Hematological Malignancies)
- ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas)
- ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
- Partnered Products and Programs
- Kisqali®(ribociclib) CDK4/6 inhibitor (Oncology)
- Balversa® (erdafitinib) FGFr inhibitor (Oncology)
- AZD5363 PKB/Akt Inhibitor (Oncology)
- Multiple Targets and Therapeutic Areas
- Pyramid™ Discovery Platform
- Oncology and CNS Discovery
- Sustaining Innovation
|Phase 1||Phase 2||Phase 3|
A synthetic small molecule that acts as an antagonist of Murine Double Minute 2 (MDM2)
Ownership: ASTX295 was discovered by Astex in collaboration with the Cancer Research UK Drug Discovery Unit at Newcastle University. Astex has an exclusive license to research, develop and commercialise ASTX295 under its drug discovery alliance agreement with Newcastle University and Cancer Research Technology Limited.
Mechanism of Action: ASTX295 is a synthetic small molecule that acts as an antagonist of human Murine Double Minute 2 (MDM2; human homolog also known as HDM2). MDM2 is an E3 ubiquitin ligase which tightly regulates the level and activity of the p53 tumor suppressor. ASTX295 is designed to block the interaction of MDM2 with p53 and to restore p53 function.
Indication: Advanced Solid Tumors
How this therapy can help
ASTX295 is an investigational agent designed to target and bind to MDM2 and to block its interaction with p53. ASTX295 has the potential to activate p53 and its tumor-suppressor functions and induce antitumor responses in cancers with a wild-type p53 gene.
ASTX295 is currently being evaluated in a Phase 1/2 study in patients with advanced solid tumors characterized by wild-type p53 to determine safety, pharmacokinetics and preliminary activity.